Non-Small Cell Lung Cancer Treatment

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Compared to small cell lung cancer (the other main type), NSCLC often grows and spreads more slowly, but it can still advance and metastasize without causing noticeable symptoms early on. Treatment is individualized based on the tumor’s type and stage as well as the individual’s symptoms, lung function, overall health and goals.

To guide treatment decisions, NSCLC is classified by stage, which describes the size of the tumor, whether it has grown into nearby tissues and whether it has spread to lymph nodes or other parts of the body. 

Once the cancer stage is confirmed, the healthcare team can build a comprehensive treatment plan. Early-stage NSCLC is often treated with surgery, sometimes followed by chemotherapy, targeted therapy or immunotherapy to help reduce the risk of recurrence. For locally advanced disease, treatment may include chemotherapy, radiation therapy and immunotherapy in specific combinations. Advanced-stage NSCLC is commonly managed with systemic therapy, which may include immunotherapy, targeted therapy and chemotherapy, along with radiation therapy to address symptoms or specific cancer sites.

Surgery for non-small cell lung cancer

Surgery is often the preferred treatment for early-stage NSCLC when the tumor can be removed safely and the patient has sufficient lung function to tolerate the operation and recovery. In many cases, surgery offers the best opportunity to remove the cancer completely, particularly when it is confined to the lung and nearby lymph nodes. The healthcare team may recommend surgical treatment for:

• Stage 1 or Stage 2 NSCLC, when the cancer is localized and can be removed with clear margins
• Select stage 3 cases, typically when the cancer has responded to initial treatment, such as chemotherapy or radiation therapy, which may be administered first to shrink the tumor and improve the likelihood of complete removal
• Limited metastatic NSCLC in rare, carefully selected situations, such as when there is only one or a few areas of cancer spread and all sites can potentially be treated effectively as part of a coordinated plan

Before recommending surgery, the healthcare team will carefully consider several factors, including the location of the tumor, whether lymph nodes are involved and the patient’s overall health. Lung function testing and imaging studies may also be used to help determine whether surgery is likely to be both safe and beneficial.

Rated High Performing in Lung Cancer Surgery

Recognized in U.S. News & World Report's Best Hospitals for significantly better performance in lung cancer surgery than the national average.

Schedule an Appointment

During surgery for non-small cell lung cancer, the surgeon will remove the tumor along with a margin of healthy tissue. The excised tissue will be sent to a laboratory for microscopic examination by a pathologist, who can identify cancerous cells and check for evidence of cancer spread.

Common surgical procedures used to treat NSCLC include:

• Wedge resection – Removal of a small wedge-shaped piece of lung tissue that contains the tumor, along with a margin of surrounding healthy tissue
• Segmentectomy – Removal of a larger, anatomically defined portion of the lung (a segment)
• Lobectomy – Removal of an entire lobe of the lung, a common approach for many early-stage NSCLC tumors when the patient can tolerate it
• Pneumonectomy – Removal of an entire lung in select situations, typically when the tumor’s location or extent makes a smaller resection unsafe or unlikely to remove all cancer
• Lymph node sampling or dissection – Removal of lymph nodes near the lung to determine whether the cancer has spread, which can help confirm the stage and guide further treatment recommendations

In many cases, lymph nodes are evaluated during the same procedure as the tumor removal to provide the most complete picture of the cancer and support treatment planning.

Potential risks and side effects of surgery for non-small cell lung cancer

Any type of surgery for NSCLC is a major procedure and may temporarily affect breathing, endurance and overall comfort during recovery. Before surgery, the healthcare team will carefully evaluate the patient’s heart and lung function to confirm the procedure can be performed safely. After surgery, the team will closely monitor the patient’s recovery, help manage any symptoms and provide guidance and support to help the patient regain strength and function over time.

Possible side effects and complications of NSCLC surgery include:

• Pain, tenderness or numbness near the incision site
• Fatigue and shortness of breath during healing
• Infection, bleeding or pneumonia
• Air leakage from the lung, which may extend the hospital stay
• Blood clots, including deep vein thrombosis (DVT) or pulmonary embolism
• Irregular heartbeat or other heart-related issues

The patient should contact the healthcare team right away about potentially serious symptoms, such as fever, increasing shortness of breath, chest pain, rapid heartbeat, significant swelling in the legs or drainage from the incision.

Preparing for lung cancer surgery and recovery expectations

Before surgery, the patient will be scheduled for preoperative evaluations, which may include pulmonary function testing, imaging scans, lab work and a heart health assessment. The healthcare team may also recommend prehabilitation, such as breathing exercises, light physical activity and nutritional support to help strengthen the body before the procedure.

Recovery time can vary based on the type of surgical procedure performed and the patient’s overall health and lung function. Before discharge, the patient will receive detailed instructions on:

• Incision care and pain management
• Breathing exercises to support lung healing
• Gradually returning to daily activities
• Follow-up appointments and next steps, which may include additional treatment to reduce the risk of recurrence

Chemotherapy for non-small cell lung cancer

Chemotherapy uses powerful medications that circulate through the bloodstream to reach and destroy widespread cancer cells. For NSCLC, chemotherapy may be used in several settings depending on the features of the tumor and the goals of treatment. For instance, it may be recommended:

• Before surgery to shrink the tumor and improve the likelihood of complete removal
• After surgical removal of a stage 2 or stage 3 tumor to help reduce the risk of recurrence
• In combination with immunotherapy for enhanced treatment effectiveness
• Along with radiation therapy for stage 3 cancer
• For stage 4 NSCLC if targeted therapy is not an option
• To ease symptoms and help control the cancer if a cure is not possible

Chemotherapy is most often administered through an intravenous (IV) infusion and is typically given in a series of cycles, with planned rest periods between active treatments to allow the body time to recover. In some cases, chemotherapy may also be given as an oral medication taken by mouth.

Common chemotherapy drugs used for NSCLC include:

• Cisplatin
• Carboplatin
• Pemetrexed
• Paclitaxel
• Docetaxel
• Gemcitabine
• Vinorelbine

Potential risks and side effects of chemotherapy for non-small cell lung cancer

Because chemotherapy targets rapidly dividing cells, it can affect cancer cells as well as healthy cells that naturally divide quickly. For this reason, side effects are common. The healthcare team can provide supportive care and medications as needed to help keep the patient safe and comfortable.

Common side effects of chemotherapy include:

• Fatigue and weakness
• Nausea, vomiting and appetite changes
• Diarrhea or constipation
• Hair thinning or hair loss
• Low blood cell counts, which can increase the risk of infection or cause anemia
• Mouth sores or changes in the sense of taste
• Numbness or tingling sensations in the hands and feet (neuropathy)
• Increased risk of dehydration and electrolyte imbalances

Certain chemotherapy regimens may also affect hearing or kidney function, particularly those that include cisplatin. The healthcare team will closely monitor lab results and watch for unusual symptoms throughout treatment to help manage these risks and protect the patient’s overall health.

Preparing for chemotherapy and recovery between cycles

Before chemotherapy begins, the patient will typically undergo blood work and may receive premedications to help prevent nausea and reduce the risk of infusion-related reactions. The healthcare team will also discuss fertility preservation as appropriate, since some chemotherapy drugs can affect reproductive health.

Between chemotherapy cycles, the patient will be encouraged to focus on rest, hydration and nutrition. The healthcare team may also provide:

• Dietary guidance to help maintain body weight and strength
• Medications for nausea, bowel changes or pain
• Infection prevention strategies during periods of low blood cell counts
• Routine lab monitoring and symptom assessments
• Treatment adjustments if side effects become difficult to manage

During chemotherapy, many patients are able to continue their daily activities with some slight modifications, although pacing and rest are often important.

Radiation therapy for non-small cell lung cancer

Radiation therapy is a localized treatment that uses high-energy beams, such as X-rays or protons, to damage the DNA of cancer cells and prevent them from growing. For NSCLC, radiation therapy may be used:

• As a curative option for an early-stage tumor if surgical removal is not possible
• After surgery to target and destroy any remaining microscopic cancer cells
• In combination with chemotherapy for stage 3 cancer
• To relieve the symptoms of stage 4 NSCLC or treat specific metastatic sites, such as the brain or bones

External beam radiation therapy (EBRT) is the most commonly used delivery technique for NSCLC. In select early-stage cases, stereotactic body radiation therapy (SBRT) may be considered to deliver highly focused doses over fewer sessions.

Potential risks and side effects of radiation therapy for non-small cell lung cancer

The side effects of radiation therapy can vary based on the area of the body treated, the radiation dose and the patient’s overall health. The healthcare team will continually monitor for symptoms and provide strategies to help reduce discomfort if needed.

Possible side effects of radiation therapy include:

• Fatigue, which may intensify during treatment
• Skin irritation at the treatment site
• Sore throat or difficulty swallowing, if the esophagus is in the treatment field
• Coughing or chest discomfort
• Shortness of breath due to lung inflammation (radiation pneumonitis), which can sometimes develop weeks or months after treatment
• Long-term lung scarring (rare)

The patient should report any new or worsening symptoms—especially fever, chest pain or shortness of breath—right away.

Preparing for radiation therapy and what to expect

Before starting radiation therapy, the patient will participate in a planning session (simulation). Using highly detailed imaging scans, the healthcare team will map the tumor, determine the optimal radiation beam angles and calculate the precise treatment dose. The patient may also be fitted for a custom positioning device to help ensure accurate radiation delivery during each session.

Many patients are able to continue their normal activities during radiation therapy, although fatigue is common and sometimes disruptive. To improve comfort, the healthcare team may recommend:

• Staying well-hydrated and maintaining proper nutrition
• Eating soft foods, if swallowing becomes difficult
• Using medications to reduce throat irritation or coughing
• Getting adequate rest while remaining gently active as tolerated

Although most side effects of radiation therapy improve gradually after treatment ends, some—such as fatigue—may take longer to resolve than others.

Immunotherapy for non-small cell lung cancer

Immunotherapy is a novel treatment approach that aims to boost the natural ability of the body’s immune system to recognize and attack cancer cells. Depending on the stage of the cancer, the results of tumor testing and any prior treatments, chemotherapy for NSCLC may be considered:

• After surgery (often following chemotherapy) in select early-stage cases to help lower the risk of the cancer returning
• After chemotherapy and radiation therapy for some stage 3 tumors as a maintenance treatment to help keep the cancer under control
• As a single-agent treatment for certain patients when tumor testing and overall health suggest immunotherapy is likely to be beneficial
• In combination with chemotherapy for stage 4 NSCLC, particularly when the goals of treatment are to control cancer throughout the body and relieve symptoms

Immunotherapy is usually given through IV infusion at regular intervals. Common immunotherapy drugs used for NSCLC include:

• Pembrolizumab
• Nivolumab
• Atezolizumab
• Durvalumab
• Cemiplimab
• Ipilimumab

Potential risks and side effects of immunotherapy for non-small cell lung cancer

While many patients tolerate immunotherapy well, the treatment can sometimes cause the immune system to become overactive and attack healthy tissues. If not addressed quickly, certain side effects can become serious, such as:

• Fatigue, skin rash, itching or joint pain
• Diarrhea or colitis
• Thyroid dysfunction, which can cause weight changes, mood swings or temperature sensitivity
• Lung inflammation (pneumonitis), which may lead to coughing or shortness of breath
• Liver inflammation (hepatitis)
• Inflammation of the heart, kidneys or nervous system (rare)

The patient should seek immediate care for severe shortness of breath, chest pain, high fever, mental confusion, sudden weakness or significant diarrhea.

Preparing for immunotherapy and ongoing monitoring

Before treatment begins, the healthcare team will review the patient’s medical history and order baseline lab testing. During immunotherapy, the team will monitor the patient’s lab results and symptoms to help detect any immune-related side effects early. Additionally, the patient may be advised to:

• Track symptoms and report any changes promptly
• Schedule periodic blood tests and follow-up appointments
• Seek prompt care for unusual fatigue, coughing or diarrhea
• Discuss any autoimmune conditions, since immunotherapy may worsen them

If side effects occur, the healthcare team may pause treatment or prescribe supportive medications, such as corticosteroids.

Targeted therapy for non-small cell lung cancer

For many patients with NSCLC, targeted therapy is an important treatment option, particularly when tumor profiling (molecular testing) identifies specific genetic changes that can be treated with targeted drugs. These therapies, which are designed to interfere with cancer growth pathways, may be recommended:

• After surgery to reduce the risk of recurrence if certain tumor biomarkers are present
• For stage 4 NSCLC with actionable genetic mutations or rearrangements
• If the cancer progresses after other treatments and targeted therapy becomes appropriate

Many targeted therapies are taken orally in pill form, although some may be given through IV infusion.

For non-small cell lung cancer, common targeted therapy drug categories and examples include:

• EGFR inhibitors (osimertinib, erlotinib, gefitinib)
• ALK inhibitors (alectinib, brigatinib, lorlatinib)
• ROS1 inhibitors (crizotinib, entrectinib)
• BRAF inhibitors (dabrafenib, often combined with trametinib)
• MET inhibitors (capmatinib, tepotinib)
• RET inhibitors (selpercatinib, pralsetinib)
• KRAS G12C inhibitors (sotorasib, adagrasib)

Supportive care and symptom-focused treatments may be integrated at any stage of targeted therapy. Many patients benefit from nutritional support, pulmonary rehabilitation, smoking cessation services, pain management and psychosocial care.

Potential risks and side effects of targeted therapy for non-small cell lung cancer

The side effects of targeted therapy can vary by drug type and individual patient factors. Many side effects are manageable with dose adjustments or supportive medications. Some patients experience:

• Skin rash or dryness
• Diarrhea or appetite changes
• Fatigue
• Swelling, especially around the eyes or in the legs
• Elevated liver enzymes
• Lung inflammation (rare)

The patient should report any shortness of breath, persistent diarrhea, severe rash or other concerning symptoms right away.

Preparing for targeted therapy and ongoing care

Before starting targeted therapy, the patient may undergo additional testing to confirm the tumor biomarkers and establish baseline organ function. The healthcare team will review the patient’s medications and supplements and discuss any possible drug interactions and side effects. The patient will be instructed to:

• Take the targeted medication exactly as prescribed
• Schedule periodic lab tests and imaging scans
• Report any side effects early so the treatment can be adjusted if needed

Targeted therapy can be highly effective in select patients, but ongoing monitoring is essential to ensure safety.

Clinical trials for non-small cell lung cancer

Clinical trials are important research studies that provide patients with unique opportunities to be among the first to benefit from promising new therapies that are not yet widely available. NSCLC treatment continues to evolve at a rapid pace, and clinical trials can provide additional options to certain patients at the time of diagnosis, after surgery, during treatment for locally advanced cancer or after recurrence.

The healthcare team can explain which clinical trials are available, the eligibility requirements, what participation involves and the potential benefits and risks. In addition to accessing innovative care, a patient who chooses to enroll in a trial can contribute to research advances that may improve outcomes for current and future patients.

Frequently asked questions (FAQs) about non-small cell lung cancer treatment

Receiving an NSCLC diagnosis often leads to urgent questions about next steps, timelines and treatment options. For example, many patients ask:

• What is the best treatment for non-small cell lung cancer?

While the information provided here offers some general guidance, the best source of information is always the patient’s own healthcare team.

Benefit from world-class care at Moffitt Cancer Center

Moffitt offers highly individualized treatment for non-small cell lung cancer through a coordinated multispecialty approach that brings together thoracic oncology, radiation oncology, pulmonary medicine, pathology, diagnostic imaging, supportive care and rehabilitation services. Working together, we tailor NSCLC treatment to each patient’s unique diagnosis, cancer stage, molecular profile, overall health and preferences, with a strong emphasis on outcomes and quality of life.

If you would like to explore your treatment options for non-small cell lung cancer with a specialist in the Thoracic Oncology Program at Moffitt, you can request an appointment by calling 1-888-663-3488 or submitting a new patient registration form online. We do not require referrals.